Public Company News & Press Release Distribution

Elekta's new strategy to focus on growth and access to radiation therapy

STOCKHOLM, June 7, 2021 /PRNewswire/ -- At Elekta's (EKTA-B.ST) Capital Markets Day, CEO,Gustaf Salford, and members from his executive management team introduced the company's mid-term strategy, called Access 2025. The strategy reflects the work the company will continue to do to pursue the visi...

2021-06-07 20:44 14189

Huya Inc. Joins the Coalition to End Wildlife Trafficking Online, Leveraging Power of Livestreaming for Public Welfare

GUANGZHOU, China, June 7, 2021 /PRNewswire/ -- HUYA Inc. ("Huya" or the "Company") (NYSE: HUYA), a leading Chinese livestreaming platform, has joined the Coalition to End Wildlife Trafficking Online (the "Coalition") for World Environment Day which fell onJune 5. It hopes to clean up further th...

2021-06-07 20:31 7801

Huya Inc. Joins the Coalition to End Wildlife Trafficking Online, Leveraging Power of Livestreaming for Public Welfare

Ambow Education Inks Strategic Cooperation Agreement with Kylinsoft

BEIJING, June 7, 2021 /PRNewswire/ -- Ambow Education Holding Ltd. ("Ambow" or "the Company") (NYSE American: AMBO),China's leading provider of educational and career enhancement services, today announced it has entered into a cooperation agreement ("Cooperation Agreement") with Kylinsoft, a lead...

2021-06-07 20:30 6495

Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient

SYDNEY, June 7, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II study of Kazia's investigational new drug, paxalisib, in primary CNS lymphoma has been initiated at Dana-Farber Cancer Ins...

2021-06-07 20:00 7238

RedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study

The global Phase 2/3 study of orally-administered opaganib for the treatment of severe COVID-19 enrolled a total of 475 patients, more than the planned 464 Opaganib is uniquely positioned as a leading novel, dual-action, investigational COVID-19 oral pill Blinded blended mortality rates encourag...

2021-06-07 19:00 5419

Tantech Announces Closing of US$7.0 Million Offering

LISHUI, China, June 7, 2021 /PRNewswire/ -- Tantech Holdings Ltd (NASDAQ: TANH) ("Tantech" or the "Company"), a clean energy company inChina, today announced that it closed a previously announced private placement transaction (the "Private Placement"), raising approximatelyUS$7.0 million in gross...

2021-06-07 19:00 7476

Clarivate Forecasts Nearly 70% of North American, European and Asia Pacific Adult Populations Will Be Vaccinated for COVID-19 by September 2021

New report analyzes how the emergence and increased availability of vaccines will impact the recovery of healthcare markets across the globe LONDON, June 7, 2021 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of inn...

2021-06-07 16:15 6673

Clarivate Forecasts Nearly 70% of North American, European and Asia Pacific Adult Populations Will Be Vaccinated for COVID-19 by September 2021

Elekta and Philips deepen strategic partnership in precise and individualized oncology care

STOCKHOLM and AMSTERDAM, June 7, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) and Royal Philips (NYSE: PHG, AEX: PHIA) today signed agreements to deepen their existing strategic partnership to advance comprehensive and personalized cancer care through precision oncology solutions. The extended collab...

2021-06-07 16:02 6723

WeChat Pay HK and Visa Collaborate to Support Disbursement of Hong Kong SAR Government's Consumption Voucher Scheme

* Collaboration aims to boost economic recovery and digital transformation of small and medium-sized businesses inHong Kong * WeChat Pay HK to waive service fee transactions for "WeChat Pay HK Checkout" merchants during the scheme period; Visa to invest in driving consumptionvoucher usage HON...

2021-06-07 15:30 17026

Aker Solutions Extends Relationship with Cognizant to Modernize its IT Systems and Help Speed Transition to Renewable Energy

By transforming and modernizing its IT Systems, Aker Solutions can offer more flexibility and faster time-to-market for its oil and gas customers TEANECK, N.J., June 7, 2021 /PRNewswire/ -- Cognizant (Nasdaq: CTSH) announced today that it has extended its relationship with global engineering com...

2021-06-07 15:30 9071

Aker Solutions Extends Relationship with Cognizant to Modernize its IT Systems and Help Speed Transition to Renewable Energy

By transforming and modernizing its IT Systems, Aker Solutions can offer more flexibility and faster time-to-market for its oil and gas customers TEANECK, N.J., June 7, 2021 /PRNewswire/ -- Cognizant (Nasdaq: CTSH) announced today that it has extended its relationship with global engineering com...

2021-06-07 15:30 14344

USANA Malaysia once again named No. 1 combination dietary supplements brand in the country by leading market research company

USANA Malaysia honored by Euromonitor International for third year in a row KUALA LUMPUR, Malaysia, June 6, 2021 /PRNewswire/ -- To be recognized as the top company in your industry is an honor few ever achieve—one USANA Malaysia has now earned for the third year in a row. USANA was recently nam...

2021-06-07 10:22 11876

Alphamab Oncology Presents Phase 2 Clinical Data on KN046 Plus Paclitaxel/Cisplatin for the First-line Treatment of ESCC at ASCO 2021

SUZHOU, China, June 7, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced data from Phase 2 clinical study (KN046-204) of KN046(PD-L1/CTLA-4 bispecific antibody) plus paclitaxel/cisplatin for the first-line treatment of unresectable locally advanced, recurrent or metastatic e...

2021-06-07 10:11 7221

Alphamab Oncology Presents Phase 2 Clinical Data on KN046 Combined with Chemotherapy for the Treatment of Advanced NSCLC at ASCO 2021

* KN046 combined with platinum doublet chemotherapy is tolerated and has shown promising clinical benefit as IL treatment for stage IV NSCLC. * OS rate at 12 months and 15 months were both 74.9%; Similar survival was observed in patients with PD-L1≥1% and PD-L1<1%; * the median progression-f...

2021-06-07 10:10 6676

Poster Highlighting Clinical Data of KN046 Plus Nab-Paclitaxel/Gemcitabine as First-Line Treatment for Pancreatic Cancer Is Presented at ASCO 2021

* As of January 15, 2021, 9 patients were included in the efficacy analysis and 17 patients in the safety analysis. ORR was 55.6%, and DCR was 88.9%. * The updated results from this Phase II study will be presented at an upcoming medical meeting. A phase III clinical study of KN046 in combinat...

2021-06-07 09:53 6740

CSOP Asset Management Ltd. Chooses SS&C to Support Operations

WINDSOR, Conn., June 7, 2021 /PRNewswire/ -- SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced thatHong Kong's CSOP Asset Management Ltd. has selected Eze Investment Suite for order management and portfolio accounting. Eze Investment Suite provides the flexibility CSOP required for ...

2021-06-07 09:00 11262

Ascletis Received China IND Approval of Its FXR Agonist ASC42 for Chronic Hepatitis B Indication

HANGZHOU, China and SHAOXING, China, June 7, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for its drug candidate ASC42 to conduct clinical trials for ch...

2021-06-07 08:30 4077

Innovent Releases Phase 1 Results of Pemigatinib in Chinese Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021

SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...

2021-06-07 08:00 8736

Innovent Releases the Phase Ia/Ib Dose-Escalation Trial Results of IBI110 (anti-LAG-3) in Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021

SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...

2021-06-07 08:00 8839

Innovent and AnHeart Release Preliminary Results from the Phase II TRUST Trial of Taletrectinib in ROS1 Fusion Positive NSCLC at the ASCO 2021 Annual Meeting

SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...

2021-06-07 08:00 8699